UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Bruck Claudine		Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol Annovis Bio, Inc. [ANVS]					
(Last) (First) (Middle) C/O ANNOVIS BIO, INC., 1055 WESTLAKES DRIVE, SUITE 3	_X_ Di	4. Relationship of Reporting Pe _X_Director Officer (give title below)		Person(s) to Issuer (Check all applicable) 10% Owner Other (specify below)					
(Street) BERWYN, PA 19312 (City) (State) (Zip)	5. If Ar	5. If Amendment, Date 6. Individual or Joint/Group I Original Filed(MM/DD/YYYY) -X_Form filed by One Reporting Per Form filed by More than One Rep			Joint/Group Filing	n			
	Tab		Derivative Secu		ially Owned				
1.Title of Security (Instr. 4)			Amount of Sec eneficially Own astr. 4)		-	4. Nature of Indirect Beneficial Owners (Instr. 5)			
Table II - Derivati	ve Securities	Beneficiall	y Owned (<i>e.g.</i> ,	, puts, calls, w	arrants, options,	convertible secu	urities)		
1. Title of Derivate Security (Instr. 4)		Diration Date S M/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)			
Convertible Note	<u>(1)</u>	<u>(1)</u>	Common Stock	<u>(1)</u>	(1)	D			
Series A-1 Preferred Stock	<u>(2)</u>	<u>(2)</u>	Common Stock	5556	(2)	D			
Stock Option (right to buy)	<u>(3)</u>	4/6/2028	Common Stock	24997	\$0.14	D			
Stock Option (right to buy)	<u>(3)</u>	4/7/2026	Common Stock	7142	\$0.25	D			

Explanation of Responses:

- (1) The Convertible Notes have a maturity date of December 31, 2023. Prior to the maturity date, the Convertible Notes will automatically convert into common stock of Annovis Bio, Inc. ("Annovis") upon an initial public offering ("IPO") of Annovis at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by 80% of the public offering price per share of the IPO as set forth on the cover page of the final prospectus for the IPO.
- (2) Each share of Series A-1 Preferred Stock is convertible into common stock of Annovis and has no expiration date. Upon the closing of the IPO, 7,778 shares of Series A-1 Preferred Stock, along with the aggregate accrued or accumulated and unpaid dividends thereon, will automatically be converted into 5,556 shares of common stock of the Issuer.
- (3) As of the date of this report, all of the shares underlying the options are fully vested and exercisable.

Reporting Owners

Reporting Owner Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Bruck Claudine						

C/O ANNOVIS BIO, INC. 1055 WESTLAKES DRIVE, SUITE 300 BERWYN, PA 19312	X		
Signatures /s/ Maria Maccecchini Attorney-in-Fact		1/29/2020	

**Signature of Reporting Person

1/29/2020 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.